CollPlant Biotechnologies Announces Results From Non-Clinical Program Evaluating Photocurable Dermal Filler; Plans To Advance Product Candidate Into Clinical Trials

CollPlant is now moving towards clinical trials and scaling and optimizing its manufacturing to ensure readiness for the upcoming clinical trials

REHOVOT, Israel, Sept. 30, 2025 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ:CLGN), a regenerative and aesthetic medicine company developing disruptive technologies and products based on its proprietary non-animal recombinant human collagen (rhCollagen), today announced positive results from its non-clinical program evaluating its photocurable dermal filler, as well as plans to advance this product candidate into clinical trials. This novel filler represents a significant breakthrough in aesthetic medicine by uniquely integrating contouring precision, structural support, and tissue regeneration into a single treatment.